JP2017505338A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505338A5 JP2017505338A5 JP2016563903A JP2016563903A JP2017505338A5 JP 2017505338 A5 JP2017505338 A5 JP 2017505338A5 JP 2016563903 A JP2016563903 A JP 2016563903A JP 2016563903 A JP2016563903 A JP 2016563903A JP 2017505338 A5 JP2017505338 A5 JP 2017505338A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- item
- position corresponding
- composition according
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 138
- 239000008194 pharmaceutical composition Substances 0.000 claims description 87
- 238000001802 infusion Methods 0.000 claims description 48
- 102000004877 Insulin Human genes 0.000 claims description 47
- 108090001061 Insulin Proteins 0.000 claims description 47
- 239000004026 insulin derivative Substances 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 47
- 229940125396 insulin Drugs 0.000 claims description 45
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 20
- 150000001413 amino acids Chemical group 0.000 claims description 20
- 229910001424 calcium ion Inorganic materials 0.000 claims description 20
- 239000002738 chelating agent Substances 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 19
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 18
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 16
- 235000001014 amino acid Nutrition 0.000 claims description 15
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 10
- 239000002981 blocking agent Substances 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 210000004899 c-terminal region Anatomy 0.000 claims description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 206010033675 panniculitis Diseases 0.000 claims description 4
- 150000002993 phenylalanine derivatives Chemical class 0.000 claims description 4
- 210000004304 subcutaneous tissue Anatomy 0.000 claims description 4
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 claims description 4
- 101000741893 Homo sapiens POTE ankyrin domain family member E Proteins 0.000 claims description 3
- 102100038761 POTE ankyrin domain family member E Human genes 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000000539 dimer Substances 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 claims description 2
- NYCRCTMDYITATC-UHFFFAOYSA-N 2-fluorophenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1F NYCRCTMDYITATC-UHFFFAOYSA-N 0.000 claims description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 claims description 2
- 244000018436 Coriandrum sativum Species 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical group NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 229920001586 anionic polysaccharide Polymers 0.000 claims description 2
- 150000004836 anionic polysaccharides Chemical class 0.000 claims description 2
- 230000002744 anti-aggregatory effect Effects 0.000 claims description 2
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical group OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 claims description 2
- 238000009792 diffusion process Methods 0.000 claims description 2
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 claims description 2
- 229960001051 dimercaprol Drugs 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- 150000002898 organic sulfur compounds Chemical class 0.000 claims description 2
- 229960003104 ornithine Drugs 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 210000001578 tight junction Anatomy 0.000 claims description 2
- 150000003628 tricarboxylic acids Chemical class 0.000 claims description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims 2
- GKJQHSSYBJHANH-UHFFFAOYSA-N 1,1-bis(sulfanyl)propane-1-sulfonic acid Chemical compound CCC(S)(S)S(O)(=O)=O GKJQHSSYBJHANH-UHFFFAOYSA-N 0.000 claims 1
- 235000019136 lipoic acid Nutrition 0.000 claims 1
- 229960002663 thioctic acid Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- 238000001962 electrophoresis Methods 0.000 description 12
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002604 ultrasonography Methods 0.000 description 8
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 241001661426 Litus Species 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000001280 Prediabetic State Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- HMPSOEYFMTWOFC-UHFFFAOYSA-N propane-2,2-dithiol Chemical compound CC(C)(S)S HMPSOEYFMTWOFC-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- FGGPAWQCCGEWTJ-UHFFFAOYSA-M sodium;2,3-bis(sulfanyl)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(S)CS FGGPAWQCCGEWTJ-UHFFFAOYSA-M 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461926946P | 2014-01-13 | 2014-01-13 | |
| US201461926944P | 2014-01-13 | 2014-01-13 | |
| US61/926,946 | 2014-01-13 | ||
| US61/926,944 | 2014-01-13 | ||
| PCT/US2015/011202 WO2015106269A2 (en) | 2014-01-13 | 2015-01-13 | Rapid action insulin formulations and pharmaceutical delivery systems |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019014241A Division JP2019081773A (ja) | 2014-01-13 | 2019-01-30 | 速効型インスリン製剤及び医薬送達システム |
| JP2020136982A Division JP2020189875A (ja) | 2014-01-13 | 2020-08-14 | 速効型インスリン製剤及び医薬送達システム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505338A JP2017505338A (ja) | 2017-02-16 |
| JP2017505338A5 true JP2017505338A5 (enExample) | 2018-02-08 |
| JP6944780B2 JP6944780B2 (ja) | 2021-10-06 |
Family
ID=53524484
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563903A Active JP6944780B2 (ja) | 2014-01-13 | 2015-01-13 | 速効型インスリン製剤及び医薬送達システム |
| JP2019014241A Pending JP2019081773A (ja) | 2014-01-13 | 2019-01-30 | 速効型インスリン製剤及び医薬送達システム |
| JP2020136982A Pending JP2020189875A (ja) | 2014-01-13 | 2020-08-14 | 速効型インスリン製剤及び医薬送達システム |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019014241A Pending JP2019081773A (ja) | 2014-01-13 | 2019-01-30 | 速効型インスリン製剤及び医薬送達システム |
| JP2020136982A Pending JP2020189875A (ja) | 2014-01-13 | 2020-08-14 | 速効型インスリン製剤及び医薬送達システム |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US9901622B2 (enExample) |
| EP (1) | EP3094343A4 (enExample) |
| JP (3) | JP6944780B2 (enExample) |
| KR (1) | KR102351111B1 (enExample) |
| CN (1) | CN106102763A (enExample) |
| AU (1) | AU2015204491B2 (enExample) |
| BR (1) | BR112016016290A2 (enExample) |
| CA (1) | CA2936563A1 (enExample) |
| IL (1) | IL246706B (enExample) |
| WO (1) | WO2015106269A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE480278T1 (de) | 2005-09-12 | 2010-09-15 | Unomedical As | Einfürungssystem für ein infusionsset mit einem ersten und zweiten federeinheit |
| JP2013523233A (ja) | 2010-03-30 | 2013-06-17 | ウノメディカル アクティーゼルスカブ | 医療デバイス |
| WO2012123274A1 (en) | 2011-03-14 | 2012-09-20 | Unomedical A/S | Inserter system with transport protection |
| WO2013050277A1 (en) | 2011-10-05 | 2013-04-11 | Unomedical A/S | Inserter for simultaneous insertion of multiple transcutaneous parts |
| EP2583715A1 (en) | 2011-10-19 | 2013-04-24 | Unomedical A/S | Infusion tube system and method for manufacture |
| WO2014076423A1 (fr) | 2012-11-13 | 2014-05-22 | Adocia | Formulation à action rapide d'insuline comprenant un composé anionique substitué |
| WO2015106269A2 (en) | 2014-01-13 | 2015-07-16 | Thermalin Diabetes, Llc | Rapid action insulin formulations and pharmaceutical delivery systems |
| AR102869A1 (es) | 2014-12-16 | 2017-03-29 | Lilly Co Eli | Composiciones de insulina de rápida acción |
| WO2016105545A2 (en) * | 2014-12-24 | 2016-06-30 | Case Western Reserve University | Insulin analogues with enhanced stabilized and reduced mitogenicity |
| JO3749B1 (ar) | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
| CN108778370B (zh) | 2016-01-19 | 2021-10-08 | 优诺医疗有限公司 | 套管和输液装置 |
| TW201831504A (zh) * | 2016-11-21 | 2018-09-01 | 美國凱斯西方瑞瑟夫大學 | 增強穩定性之速效胰島素類似物 |
| US11174303B2 (en) | 2017-03-07 | 2021-11-16 | Case Western Reserve University | Single-chain insulin analogues stabilized by a fourth disulfide bridge |
| GB201707187D0 (en) * | 2017-05-05 | 2017-06-21 | Arecor Ltd | Novel formulations |
| GB201707189D0 (en) * | 2017-05-05 | 2017-06-21 | Arecor Ltd | Novel formulations |
| CN110662551B (zh) | 2017-06-01 | 2023-07-18 | 伊莱利利公司 | 速效胰岛素组合物 |
| WO2019050749A1 (en) * | 2017-09-08 | 2019-03-14 | Eli Lilly And Company | PHARMACEUTICAL COMBINATIONS COMPRISING INSULIN AND AT LEAST ONE AGENT SELECTED AMONG MELOXICAM, BROMFENAC SODIUM, ACETYLSALICYLIC ACID, SALICYLIC ACID AND PARACETAMOL |
| CN108489941B (zh) * | 2018-01-31 | 2021-07-27 | 吉林大学 | 溴酚蓝在作为检测牛胰岛素淀粉样纤维探针和作为牛胰岛素淀粉样纤维抑制剂方面的应用 |
| CA3094237A1 (en) * | 2018-04-04 | 2019-10-10 | Arecor Limited | Medical infusion pump system for the delivery of an insulin compound |
| EP3853246A4 (en) * | 2018-09-21 | 2023-01-11 | Case Western Reserve University | Site 2 single-chain insulin analogues |
| WO2020236762A2 (en) * | 2019-05-17 | 2020-11-26 | Case Western Reserve University | Variant single-chain insulin analogues |
| SG11202111673SA (en) | 2019-05-20 | 2021-11-29 | Unomedical As | Rotatable infusion device and methods thereof |
| EP4051337A4 (en) * | 2019-10-30 | 2023-11-01 | Thermalin Inc. | DRUG RELEASE SYSTEMS, DEVICES AND METHODS |
| NL2025679B1 (en) * | 2020-05-26 | 2021-12-13 | Johanna Daams Brechtje | Electrical stimulation for preventing or treating nitric oxide deficiency related conditions |
| US20220386905A1 (en) * | 2021-03-02 | 2022-12-08 | Pacific Diabetes Technologies Inc | Signal processing algorithm for improving accuracy of a continuous glucose sensor and a combined continuous glucose sensor and insulin delivery cannula |
| KR102678960B1 (ko) * | 2021-08-26 | 2024-06-27 | 주식회사 에이피알 | 바디 관리기 |
| US20240149021A1 (en) * | 2022-11-04 | 2024-05-09 | Becton, Dickinson And Company | Intravenous Catheter Securement Sleeve |
| US20240216649A1 (en) * | 2023-01-03 | 2024-07-04 | Becton, Dickinson And Company | Management of Catheters and Accessories During Intravascular Catheter Maintenance |
| US20250242110A1 (en) * | 2024-01-26 | 2025-07-31 | Medtronic Minimed, Inc. | Fluid delivery filters |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK134691D0 (da) * | 1991-07-12 | 1991-07-12 | Novo Nordisk As | Apparat |
| US5461031A (en) * | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
| AR012894A1 (es) * | 1997-06-13 | 2000-11-22 | Lilly Co Eli | Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma. |
| WO2001000674A1 (en) * | 1999-06-29 | 2001-01-04 | Eli Lilly And Company | Insulin crystals for pulmonary administration |
| AU2002346491A1 (en) * | 2001-12-19 | 2003-07-09 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
| US20080090753A1 (en) * | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| WO2007081824A2 (en) | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Fibrillation resistant proteins |
| AU2007238114B2 (en) * | 2006-04-12 | 2010-10-14 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
| WO2008043033A2 (en) | 2006-10-04 | 2008-04-10 | Case Western Reserve University | Fibrillation-resistant insulin and insulin analogues |
| US9220837B2 (en) * | 2007-03-19 | 2015-12-29 | Insuline Medical Ltd. | Method and device for drug delivery |
| EP2132576B1 (en) * | 2007-03-30 | 2016-08-17 | Instrumentation Laboratory Company | Adaptor for sample vial |
| WO2009129250A2 (en) | 2008-04-14 | 2009-10-22 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
| NZ588857A (en) | 2008-04-22 | 2012-07-27 | Univ Case Western Reserve | Isoform-specific insulin analogue for control blood sugar levels |
| KR20120129875A (ko) * | 2008-07-31 | 2012-11-28 | 케이스 웨스턴 리저브 유니버시티 | 염소화 아미노산을 갖는 인슐린 유사체 |
| MX2011001181A (es) * | 2008-07-31 | 2011-04-05 | Univ Case Western Reserve | Insulina estabilizada con halogeno. |
| US9200053B2 (en) | 2008-07-31 | 2015-12-01 | Case Western Reserve University | Insulin analogues containing penta-fluoro-Phenylalanine at position B24 |
| US8481485B2 (en) * | 2008-12-19 | 2013-07-09 | Indiana University Research And Technology Corporation | Insulin analogs |
| US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
| WO2011028813A2 (en) | 2009-09-01 | 2011-03-10 | Case Western Reserve University | Insulin analogues of enhanced receptor-binding specificity |
| US8399407B2 (en) * | 2009-09-17 | 2013-03-19 | Case Western Reserve University | Non-standard insulin analogues |
| MY189079A (en) * | 2009-12-11 | 2022-01-25 | Univ Case Western Reserve | Insulin analogues with chlorinated amino acids |
| EA201201164A1 (ru) | 2010-02-22 | 2013-04-30 | Кейз Вестерн Ризев Юнивесити | Препараты на основе аналогов инсулина пролонгированного действия в растворимой и кристаллической формах |
| WO2013010048A2 (en) | 2011-07-13 | 2013-01-17 | Case Western Reserve University | Non-standard insulin analogues |
| WO2014145593A2 (en) | 2013-03-15 | 2014-09-18 | Case Western Reserve University | Site 2 insulin analogues |
| CN104010652A (zh) | 2011-10-27 | 2014-08-27 | 卡斯西部储备大学 | 超浓缩的速效胰岛素类似物制剂 |
| ES2574761T3 (es) * | 2011-10-31 | 2016-06-21 | Xeris Pharmaceuticals, Inc. | Formulaciones para el tratamiento de la diabetes |
| JP2015507916A (ja) | 2012-01-20 | 2015-03-16 | ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ | グルタミン酸安定化インスリン類似体 |
| US9381247B2 (en) * | 2012-04-16 | 2016-07-05 | Biodel Inc. | Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain |
| US9624287B2 (en) | 2012-07-17 | 2017-04-18 | Case Western Reserve University | O-linked carbohydrate-modified insulin analogues |
| KR102163936B1 (ko) | 2012-11-05 | 2020-10-13 | 케이스 웨스턴 리저브 유니버시티 | 장기-활성 싱글-체인 인슐린 유사체 |
| CA2937532A1 (en) * | 2013-01-22 | 2014-07-31 | Case Western Reserve University | N-terminal truncated insulin analogues |
| WO2015106269A2 (en) | 2014-01-13 | 2015-07-16 | Thermalin Diabetes, Llc | Rapid action insulin formulations and pharmaceutical delivery systems |
| JP6829928B2 (ja) | 2014-10-06 | 2021-02-17 | ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ | 二相性単鎖インスリン類似体 |
| WO2016064606A1 (en) | 2014-10-20 | 2016-04-28 | Case Western Reserve University | Halogenated insulin analogues of enhanced biological potency |
| WO2016105545A2 (en) | 2014-12-24 | 2016-06-30 | Case Western Reserve University | Insulin analogues with enhanced stabilized and reduced mitogenicity |
| EP3247720A4 (en) | 2015-01-20 | 2018-06-06 | Case Western Reserve University | Insulin analogues with selective signaling properties and reduced mitogenicity |
-
2015
- 2015-01-13 WO PCT/US2015/011202 patent/WO2015106269A2/en not_active Ceased
- 2015-01-13 CA CA2936563A patent/CA2936563A1/en active Pending
- 2015-01-13 CN CN201580013125.0A patent/CN106102763A/zh active Pending
- 2015-01-13 AU AU2015204491A patent/AU2015204491B2/en active Active
- 2015-01-13 EP EP15735454.9A patent/EP3094343A4/en not_active Withdrawn
- 2015-01-13 KR KR1020167021822A patent/KR102351111B1/ko active Active
- 2015-01-13 BR BR112016016290A patent/BR112016016290A2/pt not_active Application Discontinuation
- 2015-01-13 JP JP2016563903A patent/JP6944780B2/ja active Active
- 2015-01-13 US US15/110,758 patent/US9901622B2/en active Active
-
2016
- 2016-07-11 IL IL246706A patent/IL246706B/en active IP Right Grant
-
2018
- 2018-01-12 US US15/869,350 patent/US10561711B2/en active Active
-
2019
- 2019-01-30 JP JP2019014241A patent/JP2019081773A/ja active Pending
-
2020
- 2020-01-02 US US16/732,606 patent/US20200138911A1/en not_active Abandoned
- 2020-08-14 JP JP2020136982A patent/JP2020189875A/ja active Pending
-
2021
- 2021-06-01 US US17/335,141 patent/US20210386831A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505338A5 (enExample) | ||
| JP6944780B2 (ja) | 速効型インスリン製剤及び医薬送達システム | |
| CN102245624B (zh) | 基于酰胺的胰岛素前药 | |
| JP4959005B2 (ja) | 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療 | |
| US11174303B2 (en) | Single-chain insulin analogues stabilized by a fourth disulfide bridge | |
| JP2014159431A (ja) | 血糖降下剤の投与方法 | |
| JP2016512255A5 (enExample) | ||
| RU2012153753A (ru) | Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов | |
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| CA2302255A1 (en) | Fracture healing using pthrp analogs | |
| BR112014015156A2 (pt) | análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira | |
| EP3706774A1 (en) | Glp-2 analogs and peptibodies for administration before during, or after surgery | |
| WO2020236762A3 (en) | Variant single-chain insulin analogues | |
| EP4144362A1 (en) | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition | |
| RU2006103280A (ru) | Производные инсулина | |
| JPWO2003064462A1 (ja) | Ｐｅｇ結合ｐｔｈ又はｐｅｇ結合ｐｔｈ誘導体 | |
| WO2005016953A2 (en) | Antagonistic analogs of gh-rh (2003) | |
| Cázares-Delgadillo et al. | Human growth hormone: new delivery systems, alternative routes of administration, and their pharmacological relevance | |
| JP2019533004A (ja) | ｈＧＨ融合タンパク質を含有する、成長ホルモン欠乏症を治療するための医薬組成物 | |
| JP6049625B2 (ja) | 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 | |
| JP2017537065A (ja) | 生物学的作用強度の高いハロゲン化インスリン類似体 | |
| JP3638316B2 (ja) | イオントフォレシス用マトリックス | |
| Kesavadev et al. | Newer insulins on the horizon | |
| CA3149925A1 (en) | Premixed ultra-stable single-chain insulin analogue formulations | |
| RU2021106892A (ru) | Составы аналогов глюкагоноподобного пептида-2 (glp-2) |